Bio News
Lisata Therapeutics has acquired Marea Therapeutics through a stock exchange transaction and secured $225 million (approximately 301.5 billion won) in funding.
Investment firms including Forbion, VenBio and Third Rock Ventures are providing the funding to support Marea’s clinical plans.
Marea’s MAR001/005, which it licensed from Novartis, is being evaluated in a phase 2b trial for severe hypertriglyceridemia, while MAR002 is being evaluated in a phase 2 trial for acromegaly. Results from both trials are expected in the fourth quarter of 2027.
BIOBOOK TEAM
biobookmedia@biobook.co.krAspen Neuroscience and Bambusa Plan U.S. IPOs; Developers of Parkinson’s and Bispecific Antibody Therapies
St. Jude Identifies Cell Marker for High-Risk Neuroblastoma
University of Texas at Austin Develops Flexible Electrode for Recording Brain Waves for a Month Without Shaving Hair
Revolution Medicines Shares Fall 6.3% on Concerns About RASONK’s KRAS Subgroup
GSK Adopts Chai Discovery AI Model After Wet-Lab Validation
Teva Wins FDA Approval for Long-Acting Olanzapine Beltruzza for Schizophrenia
Peptone nears end of two-year Lilly technology evaluation…follow-on deal could be pivotal
HLB Pharmaceutical Completes 60.8 Billion Won Rights Offering, Bets on New Hyangnam Plant as Management Participation Grows
Song Young-sook sells 86 billion won stake; buyer is daughter’s one-person company — Is a second round of Hanmi control battle looming?
